||Information about asenapine sublingual wafers (Saphris) for schizophrenia and acute and maintenance treatment of manic and mixed episodes in bipolar I disorder. Asenapine has a similar spectrum of benefits and harms to that of other antipsychotics.
|Oxycodone with naloxone
||Information about oxycodone-with-naloxone controlled-release (CR) tablets (Targin) for chronic severe pain. The tablets provide equivalent analgesia to that of oxycodone CR tablets, with reduced opioid-induced constipation.
||Information on indacaterol as a once-daily, maintenance bronchodilator treatment of airflow limitation in patients with chronic obstructive pulmonary disease (COPD).
||Ticagrelor (Brilinta) and aspirin reduces the incidence of vascular deaths and myocardial infarctions more than clopidogrel and aspirin, but this must be weighed against an increased risk of adverse events.
|Brief item: losartan
||Generic losartan (Cozavan) was PBS listed on 1 December 2011. It is the first generic angiotensin II-receptor antagonist to be listed.
|Brief item: budesonide with eformoterol
||Information on budesonide with eformoterol in treatment of moderate to severe chronic obstructive pulmonary disease in people with frequent symptoms despite long-acting bronchodilator use and/or a history of recurrent exacerbations.
|Brief item: paliperidone
||Long-acting intramuscular injectable form of paliperidone (Invega Sustenna) for schizophrenia.
|Brief item: dabigatran safety update
||The Therapeutic Goods Administration published a Safety Advisory on 3 November 2011 regarding the risk of bleeding in people using dabigatran.
|NPS RADAR December 2011
||NPS RADAR articles provide timely, independent, evidence-based assessment of new drugs, new PBS listings and research for health professionals.